For other diseases, such as atypical hemolytic uremic syndrome, prophylactic treatment with complement C5 inhibitor (eculizumab) prevents disease recurrence in most patients and dramatically changed outcomes of KTx (18). Here, C5 is linked to atypical hemolytic-uremic syndrome.